Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2008

View Archived Issues

Novel antibacterial agents reported in recent patent literature

Recent patents disclose new compounds for treating cancer

Neurogen suspends phase II/III insomnia study of adipiplon

Erythropoietin shows benefits for motoneuron degeneration treatment in preclinical studies

A novel positive allosteric modulator of nAChR7 under preclinical development for schizophrenia

European Commission grants orphan designation to Marqibo for ALL

Abraxis receives approval to market Abraxane for breast cancer in China

Amgen presents positive top-line denosumab results from phase III pivitol trial

Clinical results from blonanserin for the treatment of cognitive deficits in schizophrenia

Medarex provides updates on antibody development

Cardiome reports positive phase IIb data for oral vernakalant

FDA approves OncoGenex's SPA for phase III trial of OGX-011 in HRPC

NanoViricides reports excellent efficacy of EKC-Cide in first animal study

ValiRx to acquire Cronos Therapeutics

Edison's second-generation coenzyme Q10 analogue enters phase I clinical trials

Moderate efficacy of ARG-201 in patients with late-phase systemic sclerosis / News in Context

Luminex and ViroNovative sign license agreement for human metapneumovirus rights

Map commences phase III MAP-0004 trial in patients with migraine

Theravance presents clinical results from its LAMA Respiratory Program

FDA accepts Genta's amendment to NDA for Genasense in CLL as complete response

MRC and Biolex successfully complete collaboration to humanize BLX-301

Immunomedics enters worldwide license agreement with Nycomed for veltuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...